Periodic Reporting for period 1 - SenseGuard (SenseGuard – A breakthrough respiratory monitoring device incorporating novel nanotechnology-based sensors)
Período documentado: 2019-05-01 hasta 2019-09-30
Disease monitoring is key for patients with chronic respiratory conditions. Chronic Obstructive Pulmonary Diseases (COPD) is a long-term condition that causes inflammation in the lungs, making breathing difficult. It is a large growing public health problem, expected to become one of the leading causes of death by 2030. Nevertheless, COPD patients lack of a constant and accurate monitoring throughout their disease. This can result in non-adequate therapeutic measures, which can often lead to potential serious effects on patient’s status and high costs for healthcare systems.
SenseGuard™ is a reliable solution for monitoring of patients with respiratory diseases, including COPD, based on a unique nanosensor-based technology. It is an innovative wireless wearable device that enables continuous and non-invasive monitoring of lung functions derived from patients' tidal (normal) breathing.
SenseGuard™ is a reliable solution for monitoring of patients with respiratory diseases, including COPD, based on a unique nanosensor-based technology. It is an innovative wireless wearable device that enables continuous and non-invasive monitoring of lung functions derived from patients' tidal (normal) breathing.
From 1 May until 30 September 2019, NanoVation G.S. Ltd. used Phase 1 funding to carry out an extensive study to identify the technical and business requirements to deliver a finished and legally approved commercial version of SenseGuard™.
In terms of technical outcomes, NV produced a complete Product Development Plan, detailing the main steps to make SenseGuard™. ready for the market: product finalisation, industrialisation, validation, and CE Mark application. Regarding the business outcomes of the Phase 1 analysis, NV reviewed in detail its business model and commercialization plan to define the best approach for an accelerated and effective market uptake.
In terms of technical outcomes, NV produced a complete Product Development Plan, detailing the main steps to make SenseGuard™. ready for the market: product finalisation, industrialisation, validation, and CE Mark application. Regarding the business outcomes of the Phase 1 analysis, NV reviewed in detail its business model and commercialization plan to define the best approach for an accelerated and effective market uptake.
Chronic respiratory diseases such as COPD, receive little attention and funding in comparison with other major causes of global morbidity and mortality. Accurate, constant monitoring of COPD patients is crucial to manage exacerbation and minimise outcome severity and costly intervention. SenseGuard™ will contribute to effective therapies and treatment, which will also lead to decreased healthcare costs. By remotely monitoring COPD patients at home, SenseGuard™ will help to reduce admissions in hospitals and thus associated costs for healthcare facilities, thanks to early detection and timely intervention.